Observational studyBMC women's health2025
Human papillomavirus infection among patients with cervical cancer in Cambodia.
Observational study in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the second-most common cancer among Cambodian women, with an estimated 1274 new cases and 670 deaths annually. On October 5, 2023, the Cambodian government introduced HPV vaccination for 9-year-old girls into the country's national immunization schedule. The optimal strategy for this nascent vaccination campaign, and the expected effects thereof, depend on a robust understanding of HPV epidemiology in Cambodia. To this end, we conducted a retrospective, observational, cross-sectional study of HPV infection among patients with cervical cancer at Calmette Hospital in Phnom Penh, Cambodia.
methodsFifty specimens of formalin-fixed, paraffin-embedded cervical tumor tissue selected from archival specimens of biopsies performed at Calmette Hospital between April 2019 to March 2020 were analyzed using next-generation sequencing to detect HPV types present in each sample. Forty-seven samples of non-cancerous cervical tissue were selected for comparison from archival specimens of non-oncological hysterectomies performed at Cambodia's National Maternal and Child Health Center between January 2020 to March 2021 and analyzed using PCR, gel electrophoresis, and p16 immunohistochemistry to detect the presence of HPV infection in each sample. Those that tested positive for HPV underwent next generation sequencing to detect which HPV subtypes were present in each sample.
resultsHPV-16/18 were detected in 83.3% of cervical cancer specimens, and HPV-58 was detected in 11.9%. Multiple HPV subtypes were detected in 2.4% of cancer specimens. Neither HPV-16 nor - 18 differed statistically in observed prevalence from either those rates reported for all Asia or globally. The observed prevalence of HPV-58 was not dissimilar between Cambodia and Asia, however Cambodia's prevalence of HPV-58 was substantially higher than the global rate. HPV DNA was detected in 0/47 control specimens.
conclusionThis is the first study of HPV type prevalences among patients with cervical cancer in Cambodia, providing epidemiological data that is crucial for assessing and optimizing the country's vaccination policy. Results suggest that the efficacy of current vaccination strategy should not be hindered by any outsized prevalence of non-vaccine type HPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.